Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 8.01 (Other Events). FDA Breakthrough Therapy Designation for elsunersen, accelerating development and regulatory interactions.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Breakthrough Therapy Designation for elsunersen, accelerating development and regulatory interactions
- Target indication: seizures from gain-of-function SCN2A Developmental and Epileptic Encephalopathy
- Designation supported by positive topline EMBRAVE Part A results in nine pediatric patients aged 2–12
- Potentially strengthens elsunersen’s regulatory and commercial positioning, but efficacy remains based on early-stage data
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.